|
[1]ZHANG LX,WANG F,WANG L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.
|
|
[2]CHEN YC,SU YC,LI CY,et al.13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan[J].BMC Nephrol,2015,16:110.
|
|
[3]CAI JF,FAN XH,MOU LJ,et al.Association of reduced renal function with hepatitis B virus infection and elevated alanine aminotransferase[J].Clin J Am Soc Nephrol,2012,7(10):1561-1566.
|
|
[4]ZENG Q,GONG Y,DONG SY,et al.Association between exposure to hepatitis B virus and chronic kidney disease in China[J].J Int Med Res,2014,42(5):1178-1184.
|
|
[5]GARA N,ZHAO X,COLLINS MT,et al.Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B[J].Aliment Pharmacol Ther,2012,35(11):1317-1325.
|
|
[6]KIM Y,CHO H,SINN D,et al.Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J].J Gastroenterol Hepatol,2012,27(2):306-312.
|
|
[7]TANAKA M,SUZUKI F,SEKO Y,et al.Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B[J].J Gastroenterol,2014,49(3):470-480.
|
|
[8]FONTANA RJ.Side effects of long-term oral antiviral therapy for hepatitis B[J].Hepatology,2009,49(5 Suppl):s185-s195.
|
|
[9]FERNANDEZ-FERNANDEZ B,MONTOYA-FERRER A,SANZ AB,et al.Tenofovir nephrotoxicity:2011 update[J].AIDS Res Treat,2011,2011:354908.
|
|
[10]IZZEDINE H,LAUNAY-VACHER V,DERAY G.Antiviral drug-induced nephrotoxicity[J].Am J Kidney Dis,2005,45(5):804-817.
|
|
[11]TERRAULT NA,BZOWEJ NH,CHANG KM,et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology,2016,63(1):261-283.
|
|
[12]IZZEDINE H,HULOT JS,LAUNAY-VACHER V,et al.Renal safety of adefovir dipivoxil in patients with chronic hepatitis B:two double-blind,randomized,placebo-controlled studies[J].Kidney Int,2004,66(3):1153-1158.
|
|
[13]HERLITZ LC,MOHAN S,STOKES MB,et al.Tenofovir nephrotoxicity:acute tubular necrosis with distinctive clinical,pathological,and mitochondrial abnormalities[J].Kidney Int,2010,78(11):1171-1177.
|
|
[14]HWANG HS,PARK CW,SONG MJ.Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection[J].Hepatology,2015,62(4):1318-1320.
|
|
[15]FUNG J,SETO WK,LAI CL,et al.Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment[J].J Gastroenterol Hepatol,2014,29(3):428-434.
|
|
[16]MARCELLIN P,CHANG TT,LIM SG,et al.Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].Hepatology,2008,48(3):750-758.
|
|
[17]HADZIYANNIS SJ,TASSOPOULOS NC,HEATHCOTE EJ,et al.Long-term therapy with adefovir dipivoxil for HBeA g-negative chronic hepatitis B for up to 5 years[J].Gastroenterology,2006,131(6):1743-1751.
|
|
[18]QI X,WANG JY,MAO RC,et al.Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B:a prospective cohort study in China[J].J Viral Hepat,2015,22(1):46-54.
|
|
[19]HA NB,HA NB,GARCIA RT,et al.Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil[J].Hepatology,2009,50(3):727-734.
|
|
[20]MALLET V,SCHWARZINGER M,VALLET-PICHARD A,et al.Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection[J].Clin Gastroenterol Hepatol,2015,13(6):1181-1188.
|
|
[21]TIAN JH,HE YQ,MA XY,et al.The observation of blood serum creatinine and phosphorus during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J].Chin J Hepatol,2013,21(3):239-240.(in Chinese)田敬华,何艳群,马小艳,等.慢性乙型肝炎患者在阿德福韦酯治疗期间的肌酐和血磷水平变化[J].中华肝脏病杂志,2013,21(3):239-240.
|
|
[22]HE LL,PANG YF,ZHAO DB.Two cases of hypophophataemic osteomalacia induced by the small dose of adefovir dipivoxil and literature review[J].Chin J Osteopoross,2013,19(10):1074-1079.(in Chinese)贺玲玲,庞亚飞,赵东宝.小剂量阿德福韦酯导致低血磷性骨软化症两例并文献总结[J].中国骨质疏松杂志,2013,19(10):1074-1079.
|
|
[23]LI J,LUO YL,YANG L,et al.Fanconi syndrome induced by adefovir dipivoxil in treatment of chronic hepatitis B:a report of two cases and literature review[J].Chin J Pract Intern Med,2014,34(1):79-82.(in Chinese)李俊,罗筱莲,杨莉,等.阿德福韦酯治疗慢性乙型肝炎致Fanconi综合征2例报告并文献复习[J].中国实用内科杂志,2014,34(1):79-82.
|
|
[24]BUTI M,TSAI N,PETERSEN J,et al.Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection[J].Dig Dis Sci,2015,60(5):1457-1464.
|
|
[25]TIEN C,XU JJ,CHAN LS,et al.Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling[J].Dig Dis Sci,2015,60(2):566-572.
|
|
[26]VIGANOM,BROCCHIERI A,SPINETTI A,et al.Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal[J].J Clin Virol,2014,61(4):600-603.
|
|
[27]MAUSS S,BERGER F,FILMANN N,et al.Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B[J].J Hepatol,2011,55(6):1235-1240.
|
|
[28]GANE EJ,DERAY G,LIAW YF,et al.Telbivudine improves renal function in patients with chronic hepatitis B[J].Gastroenterology,2014,146(1):138-146.
|
|
[29]YAPALI S,LOK AS.Potential benefit of telbivudine on renal function does not outweigh its high rate of antiviral drug resistance and other adverse effects[J].Gastroenterology,2014,146(1):15-19.
|
|
[30]MANNS MP,AKARCA US,CHANG TT,et al.Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901[J].Expert Opin Drug Saf,2012,11(3):361-368.
|
|
[31]TSAI MC,CHEN CH,HUNG CH,et al.A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B:a match-control study[J].Clin Microbiol Infect,2014,20(2):o90-o100.
|
|
[32]WANG Y,THONGSAWAT S,GANE EJ,et al.Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B[J].J Viral Hepat,2013,20(4):e37-e46.
|
|
[33]CHOLONGITAS E,VASILIADIS T,GOULIS I,et al.Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease[J].J Viral Hepat,2015,22(7):574-580.
|
|
[34]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
|
|
[35]LEVIN A,STEVENS PE,BILOUS RW,et al.Kidney Disease Improving Global Outcomes(KDIGO)CKD Work Group.KDIGO2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J].Kidney Int,2013,3(1):1-150.
|
|
[36]PIPILI C,CHOLONGITAS E,PAPATHEODORIDIS G.Review article:nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J].Aliment Pharmacol Ther,2014,39(1):35-46.
|
|
[37]LOK AS,McM AHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):661-662.
|
|
[38] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.
|
|
[39]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update[J].Hepatol Int,2012,6(3):531-561.
|
|
[40]PIPILI CL,PAPATHEODORIDIS GV,CHOLONGITAS EC.Treatment of hepatitis B in patients with chronic kidney disease[J].Kidney Int,2013,84(5):880-885.
|
DownLoad: